(PDF) P116 Real World Data of 1st Line A+T in Advanced

P116 Real World Data of 1st Line A+T in Advanced EGFR+ NSCLC: Clinical Outcome, PFS Influential Factors and Acquired Resistance

Journal of Thoracic Oncology - United States

doi 10.1016/j.jtho.2018.10.142

Full Text

Abstract

Available in full text

Categories

Respiratory Medicine

Date

December 1, 2018

Authors

Publisher

Elsevier BV

Related search

P3.01-85 Real-World Gefitinib 1st Line Treatment of Patients With Advanced NSCLC and EGFR Mutations - Serbian Single Center Experience

Journal of Thoracic Oncology

Respiratory Medicine

English

P1.13-11 PRO-CTCAE Toxicities in Advanced NSCLC Patients With EGFR Mutations: A Real World Assessment

Journal of Thoracic Oncology

Respiratory Medicine

English

MA15.11 Real World Biomarker Testing and Treatment Patterns in Patients With Advanced NSCLC Receiving EGFR-TKIs

Journal of Thoracic Oncology

Respiratory Medicine

English

Combined Plasma and Tissue Genotyping of EGFR T790M Benefits NSCLC Patients:A Real‐world Clinical Example

Molecular Oncology

Cancer Research

Molecular Medicine

English

Comparison of EGFR-TKI and Chemotherapy in the First-Line Treatment of Advanced EGFR Mutation-Positive NSCLC

Cancer Research

English

P1.15-03 Clinical Characteristics of Long-Term Survivors With Nivolumab in Pretreated Advanced NSCLC From Real-World Data (RWD)

Journal of Thoracic Oncology

Respiratory Medicine

English

PC05.01 Debate 1: Which Is Most Important Efficacy Endpoint in First Line Trials in Advanced NSCLC PFS or OS - Point of View: PFS

Journal of Thoracic Oncology

Respiratory Medicine

English

Real-World Experience of Afatinib as a First-Line Therapy for Advanced EGFR Mutation-Positive Lung Adenocarcinoma

English

OA03 Afatinib Followed by Osimertinib in Real-World Patients With EGFR Mutation-Positive Advanced NSCLC: The Giotag Study

Journal of Thoracic Oncology

Respiratory Medicine

English